This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
SureNano Science advances GEP-44, a next-gen GLP-1 candidate targeting obesity and metabolic disease as the market exceeds $200B. The company focuses on improved efficacy and alternative delivery options. #GLP1 #Biotech
2026-05-15T02:58:34.164Z